This study was necessary because many patients requiring intravitreal anti-VEGF injections have diabetes of advanced age, have physiologically low endothelial cell counts, and often require multiple injections, leaving their corneal endothelium vulnerable [13,14]. Here, VEGFA is linked to diabetes mellitus.